Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing/Open Innovation
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Subscribe To Our Newsletter & Stay Updated